• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Vector Partners Limited

    Biosynth Carbosynth

    Baxter BioPharma Solutions

    Qosina
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Vector Partners Limited

    Biosynth Carbosynth

    Baxter BioPharma Solutions

    Qosina
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Re-Open Your Tool Chest

    There’s no longer an excuse NOT to start “PAT-ing” your products

    Re-Open Your Tool Chest
    Related CONTENT
    • Biosynth Carbosynth
    • MedPharm
    • Coriolis Pharma
    • Mogene
    • Softweb Solutions
    Emil W. Ciurczak, DoraMaxx Consulting07.15.19
    When I was a youngster my dad gave me some good advice: “If you don’t want to do something, you’ll always find a reason not to do it. If you WANT to do something, you’ll FIND a WAY to do it.” This applies to converting from same-old, same-old GMP batch processing—and testing a miniscule portion of the final product—to real-time testing and a de facto examination, if not actual analysis of the entire lot of product.

    I have already on multiple occasions discussed the cost savings due to a speedier time to completion, less warehousing needed for intermediates, better quality control leading to fewer customer complaints and FDA/EMA mandated recalls, and so forth. The reasons were logical and based on quality, as well as financial return. However, I may have overlooked the familiarity of the personnel at smaller companies (CMOs, CROs, and smaller generic companies) with the latest hardware and software for doing PAT/QbD. No, I am not going to expound upon the wonders and rewards of continuous manufacturing or merely point out that the revolution, begun almost two decades ago, is now far easier than ever to join.

    I understand that the professionals who work at these smaller companies are as bright and educated as those at the “Big Boys.” What is different is the “loose change” available for them to attend professional meetings and seminars. As much as one can learn from websites and Google, actually attending seminars, meetings and conferences allows professionals to see the equipment and meet with their peers and exchange ideas on how to utilize the newer instruments, what they disclose, and how to use the information to control and improve a product’s manufacture.

    Certainly, a column this size cannot replace hand-on experience or even a full-sized primer; but I will highlight several pieces of new and relatively new hardware and software that can allow even the novice to dip his/her toe in the (PAT) water. Spoiler alert: you install a PAT program much as you would eat an elephant—one bite at a time.

    When the PAT (draft) Guidance was unveiled in 2004, the author (Ajaz Husaain, CDER, FDA) envisioned a company shutting down an entire production line, re-fitting all the equipment, calibrating and validating the line, training the operators and, after a year or so off-line, restarting the line under PAT. At the time, I was very, very cynical about a mass conversion to the process. Unfortunately, I was correct. However, I had a slightly different idea of how to convert the masses.

    Unknown to me at the time, I was taking the first steps into the PAT-world in 1983, when I instituted a 100% qualification of all incoming raw material containers. Looking at existing wet and instrumental methods in the USP, BP, etc., I knew that even the major Pharma company that employed me (Sandoz) would be hard-pressed to expand the QC department, buy enough equipment for the process, and absorb the costs.

    Happily, I was able to work with the foremost NIR supplier in the world at that time to develop qualitative software, generate equations, validate them, and institute NIRS for 100% of all batches of all materials entering our facility. One simple example of the time and cost savings would be a single lot of Lactose, USP. We generally received about 220 bags of the material per load—sometimes, several times a month. To check all the bags would entail:

    1. Quarantine the lot and place red/orange stickers on each bag;
    2. Open each bag;
    3. Using a sample thief, sample each bag;
    4. Label a whirl-pack and insert the sample;
    5. Bring the samples to the QC lab;
    6. Log the samples;
    7. Assign the samples (220, on the average) to an analyst;
    8. Run the wet tests and the Infrared/UV comparisons with a standard;
    9. Report the results;
    10. Have a supervisor check the results;
    11. Label each bag with an appropriate sticker (green = OK to use); and
    12. Move the bags to the part of the warehouse where approved materials reside.

    While steps 2-5 existed until portable analyzers were developed, the other steps were neatly eliminated. The materials could be sampled where they were delivered and, as we found through experience, a typical Lactose, USP lot could be sampled, bagged, brought to the lab, scanned, and approved or rejected, all before lunch. Yes, the new method, performed with newly written software on a 1982 instrument, could analyze more than 200 samples in four hours! The wet and instrumental methods, aside from requiring an entire shift to be hired, would have taken up to two weeks to analyze the same samples While not a true PAT step—this is eight years before the PAT Guidance was even written—it was the first step towards accessing information needed for a QbD program (avg. particle size, moisture, polymorphic form, crystallinity, etc.).

    These parameters were formerly measured by compendial methods, if only for checking that the correct materials were delivered. I discovered micronized API where it should have been 100-120 mesh by NIR and several bags of lactose were above the moisture limit, so 100% testing worked well. When this ability is extended to a formal SOP, we have the first under-pinning of PAT: characterization of raw materials so that we can control the process better.

    Now, we can attach a wireless spectrometer (NIR for 2% => and LIF [light-induced fluorescence] for less than 2% API) to our blender. You say you’ve never done this before? No problem, the technique and technology has been around since approximately 1990, so the instrument suppliers have the wherewithal to assist you in choosing, installing, and validating their blend uniformity equipment. Now you have step one (raw material qualification) and step two (blending), so we move on to step three (drying/granulating).

    Most major suppliers of fluid bed driers routinely supply extra ports, besides the traditional sampling port, to accommodate fiber optic probes from NIR or Raman instruments. Literature is available and the suppliers of both the driers/granulators and spectroscopic instruments are able and willing to assist with your timed conversion, then analyzed to monitor and dry/granulate to an appropriate endpoint. Since the PAT Guidance asserts that, in lieu of the minimum three “demonstration lots,” then fix your blend/granulation time via SOP, each batch is a validation batch. That is, the process continues, not to a fixed time point, but to completion.

    So, through steps three/four, depending on whether you count drying as separate from granulation, we have now finally met the legal requirement for GMP (as seen in the CFR): that “meaningful” in-process tests must be performed. Considering many of the “traditional” tests for solid dosage forms (hardness, friability, and disintegration, along with loss on drying, all off-line), with these monitors we would have control and the required measurements. That leaves the penultimate, or final, step: compression, or encapsulation.

    If the previous steps were not meaningfully checked, then the final dosage forms really, really miss the stated requirement: “a statistically significant number of final dosage forms must be tested.” Now, I’m just a simple, country chemist, but I don’t believe that analyzing 20-30 tablets from a batch of 1,000,000 to 5,000,000 units is in any way “statistically significant.” Here’s where several vendors come to the rescue. Several commercial instruments are available, and for far less than the cost of one rejected or recalled batch of product, that are capable of fully analyzing up to 100,000 tablets or capsules per hour, per line. According to military standards of testing, a batch of over 500,000 should have at least 25,000 of its units checked. Ask yourself: “which is cheaper and faster: HPLC or NIRS?”

    For those of you that coat your tablets, the prior step may be used to assure the core integrity, and a separate spectroscopic unit (NIR, Raman) may be used to measure the coating levels, in real time, assuring the proper time to completion. So, it seems that PAT is not only allowed under GMP, but aside from the money and time saved over current methods, aligns your process more closely with cGMP rules. And, as I mentioned at the start, all these need not be done in one bite, which is expensive and time-consuming. Taking one “nibble at a time” is a better approach.

    In truth, other than raw materials analysis, whichever of the other steps you update does not matter. You need not go in order. In fact, see which step is giving your operators the most trouble and start there. 

    Author’s note: specific suppliers may be obtained by contacting me via email. The column is not meant to be a commercial for specific suppliers.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • Validation
    • Pharma
    • it
    • merck
    Suggested For You
    Biosynth Carbosynth Biosynth Carbosynth
    MedPharm MedPharm
    Coriolis Pharma Coriolis Pharma
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Merck Merck
    Artificial Intelligence and Machine Learning in Healthcare Artificial Intelligence and Machine Learning in Healthcare
    Getting PAT into Bioprocessing CMOs Getting PAT into Bioprocessing CMOs
    Merck to Restructure Manufacturing Ops Merck to Restructure Manufacturing Ops
    Eisai, Purdue Pharma Amend Lemborexant Alliance Eisai, Purdue Pharma Amend Lemborexant Alliance
    Merck & NJII Receive NIIMBL Award Merck & NJII Receive NIIMBL Award
    Pharmaceutical Excipients Trends Pharmaceutical Excipients Trends
    Career Inflection Points Career Inflection Points
    Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

    Related Content

    • Biosynth Carbosynth

      Biosynth Carbosynth

      ...
      Aimee Cossins, Marketing 03.01.22

    • MedPharm

      MedPharm

      ...
      Andie Woodson, Marketing Manager 10.21.21

    • Coriolis Pharma

      Coriolis Pharma

      ...
      Daniel Weinbuch, Dr. 07.01.21


    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • LabVantage Solutions Adds Mixed Reality Technology to Its Advanced LIMS Platform
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      H.M. Royal Becomes Exclusive OCSiAl Distributor
      American Colors to Expand Sandusky, Ohio Facility
      Vaughn O’Dea Named Director of Epoxytec
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
      Agnes Lee Named SVP of Investor Relations, Strategic Planning at Inogen
      Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Past Henkel Exec Christian Chopra Named President of Scotch Porter
      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login